Leerink analyst Joseph Schwartz upgraded AN2 Therapeutics (ANTX) to Outperform from Market Perform with a $9 price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANTX:
- AN2 Therapeutics reports Q1 EPS (29c), one estimate (23c)
- AN2 Therapeutics, Inc. (ANTX) Q1 Earnings Cheat Sheet
- AN2 Therapeutics Completes First-in-Human Trial, Setting Up the Next Catalyst for ANTX
- AN2 Therapeutics Launches New $80 Million ATM Program
- AN2 Therapeutics files $300M mixed securities shelf